NEW YORK, May 14 – Aptus Genomics added $6.2 million to its coffers in its latest round of financing, the Rockville, Maryland-based company announced Monday.
Aptus develops technology platforms to discover and analyze the function of selected families of human genes. The company, founded in June 2000, is focusing initial efforts on the cell surface receptors super family.
The company is currently completing gene collection and will move to high-throughput functional assays and screening to be used for in-house drug discovery development and future partnership collaborations, Aptus CEO Kevin Chance told GenomeWeb.
The most recent round of funding came from Emerging Technology Partners, the Grosvenor Funds, and VitalBio. Aptus originally raised $1.5 million in seed funding from Emerging Technology Partners in October 2000.
The money will be used for R&D staffing, purchasing equipment, and building infrastructure, said Chance. Aptus currently has two ABI 3700 sequencers.
In June, the company is planning to move its headquarters to Gaithersburg, Maryland.